ChiCTR2600119877 版本V1.0 版本创建时间2026/03/04 17:31:57 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600119877 

最近更新日期:

Date of Last Refreshed on:

2026-03-04 17:31:52 

注册时间:

Date of Registration:

2026-03-04 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

基于富血小板血浆治疗骨性关节炎患者护理方案的构建及应用研究

Public title:

Construction and Application Study of a Nursing Care Protocol for Patients with Osteoarthritis Treated with Platelet-Rich Plasma

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于富血小板血浆治疗骨性关节炎患者护理方案的构建及应用研究

Scientific title:

Construction and Application Study of a Nursing Care Protocol for Patients with Osteoarthritis Treated with Platelet-Rich Plasma

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

苏涵昆 

研究负责人:

何览南 

Applicant:

Hankun Su 

Study leader:

Lannan He 

申请注册联系人电话:

Applicant telephone:

+86 135 6022 4077

研究负责人电话:

Study leader's
telephone:

+86 180 7513 6378

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

hankunsu@163.com

研究负责人电子邮件:

Study leader's E-mail:

395659107@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖南省长沙市桐梓坡路172号

研究负责人通讯地址:

湖南省长沙市芙蓉区解放西路61号

Applicant address:

No. 172 Tongzipo Road, Changsha City, Hunan Province, China

Study leader's address:

No. 61 Jiefang West Road, Furong District, Changsha City, Hunan Province, China

申请注册联系人邮政编码:

Applicant postcode:

410000

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中南大学湘雅医学院

Applicant's institution:

Xiangya School of Medicine, Central South University

研究负责人所在单位:

湖南省人民医院(湖南师范大学附属第一医院)

Affiliation of the Leader:

Hunan Provincial People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

[2024]-176

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

湖南省人民医院(湖南师范大学附属第一医院)医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University)

伦理委员会批准日期:

Date of approved by ethic committee:

2024-04-23 00:00:00

伦理委员会联系人:

廖前进

Contact Name of the ethic committee:

Qianjin Liao

伦理委员会联系地址:

湖南省长沙市芙蓉区解放西路61号

Contact Address of the ethic committee:

No. 61 Jiefang West Road, Furong District, Changsha City, Hunan Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 153 8757 7353

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

湖南省人民医院(湖南师范大学附属第一医院)

Primary sponsor:

Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University)

研究实施负责(组长)单位地址:

湖南省长沙市芙蓉区解放西路61号

Primary sponsor's address:

No. 61 Jiefang West Road, Furong District, Changsha City, Hunan Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖南省

市(区县):

长沙市

Country:

China

Province:

Hunan

City:

单位(医院):

湖南省人民医院(湖南师范大学附属第一医院)

具体地址:

湖南省长沙市芙蓉区解放西路61号

Institution
hospital:

Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University)

Address:

No. 61 Jiefang West Road, Furong District, Changsha City, Hunan Province, China

经费或物资来源:

湖南省人民医院(湖南师范大学附属第一医院)

Source(s) of funding:

Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University)

研究疾病:

骨关节炎  

Target disease:

Osteoarthritis

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

通过深入研究富血小板血浆(PRP)联合新运动护理干预的机制和效果,旨在构建系统科学的护理干预模式,并评估其对早中期膝关节骨性关节炎(KOA)患者的临床疗效、生活质量及护理满意度,为未来KOA的治疗提供更多有益的启示和指导方案。  

Objectives of Study:

To investigate the clinical efficacy, quality of life, and nursing satisfaction of a new exercise-based nursing intervention combined with Platelet-Rich Plasma (PRP) for early- to mid-stage knee osteoarthritis (KOA), aiming to establish a systematic and scientific nursing care model.

药物成份或治疗方案详述:

本研究采用富血小板血浆(PRP)作为主要治疗手段,并结合两种不同的护理方案进行对比。 1. PRP制备与注射: 方法:采用密度梯度离心法。 过程:在无菌环境下,抽取患者上肢静脉血15ml,使用德国Rotofix32A型离心机,以1500转/min离心5分钟。吸取上层液体3ml即为PRP。 注射:患者仰卧位屈膝90°,常规消毒后,在膝关节外侧进针,进入关节腔后回抽无阻力,注入制备好的PRP。注射后压迫进针点30秒,嘱患者屈伸膝关节数次使PRP分布均匀,1天内勿水洗进针点。 2. 护理干预方案: 对照组:接受PRP治疗的同时,给予常规护理。 观察组:接受PRP治疗的同时,实施“新运动护理干预”。该干预的核心是在PRP注射后24小时内开始进行力量和减重训练,以促进软骨和滑膜代谢修复。训练计划根据PRP注射后的急性期、亚急性期、恢复期和巩固期的不同阶段制定。 

Description for medicine or protocol of treatment in detail:

This study employed Platelet-Rich Plasma (PRP) as the primary treatment modality, combined with two distinct nursing interventions for comparison. 1. PRP Preparation and Injection: Method: Density gradient centrifugation method was used. Procedure: Under sterile conditions, 15 ml of venous blood was drawn from the patient's upper limb. A German Rotofix32A centrifuge was used at 1500 rpm for 5 minutes. The upper layer of liquid (3 ml) was aspirated as PRP. Injection:The patient lies supine with the knee flexed at 90°. After routine disinfection, the needle is inserted laterally into the knee joint. Upon entering the joint cavity (indicated by a "give" sensation), the syringe is pulled back without resistance, and the prepared PRP is injected. The puncture site is compressed for 30 seconds. The patient is instructed to flex and extend the knee several times to evenly distribute the PRP within the joint cavity, and to avoid washing the injection site for one day. 2. Nursing Intervention Protocol: Control Group: Received PRP therapy along with routine nursing care. Observation Group: Received PRP therapy along with a "new exercise-based nursing intervention". The core of this intervention involves initiating strength and weight-bearing exercises within 24 hours after PRP injection to promote cartilage and synovial metabolism and repair. Training programs were tailored according to the different phases following PRP injection: acute, subacute, recovery, and consolidation 

纳入标准:

1.接受富血小板血浆骨性关节炎治疗的患者; 2.患者明确自己的疾病诊断; 3.年龄18周岁以上; 4.意识清醒,有基本的语言交流能力; 5.血小板数量等血液指标、营养状况、体质指数、血管功能、组织氧气灌注、免疫力、神经系统功能均正常; 6.电解质、血细胞、血糖、酸碱度等全身基础条件符合要求

Inclusion criteria

1. Patients receiving platelet-rich plasma (PRP) treatment for osteoarthritis 2. Patients with a clear understanding of their diagnosis 3. Age >= 18 years 4. Conscious and alert, with basic verbal communication ability 5. Normal platelet count and other hematological parameters, nutritional status, body mass index (BMI), vascular function, tissue oxygen perfusion, immunity, and neurological function 6. Systemic baseline conditions—including electrolytes, blood cells, blood glucose, and acid-base balance—meet required standards

排除标准:

1.有精神或心理疾病史; 2.拒绝参与此研究

Exclusion criteria:

1. History of mental or psychological disorders; 2. Refusal to participate in this study

研究实施时间:

Study execute time:

From 2024-04-01 00:00:00 To 2027-05-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-04-24 00:00:00 To 2025-03-05 00:00:00

干预措施:

Interventions:

组别:

实验组

样本量:

30

Group:

Experimental group

Sample size:

干预措施:

富血小板血浆(PRP)联合新运动护理干预(即PRP注射后24小时内开始进行力量和减重训练)。

干预措施代码:

Intervention:

Platelet-rich plasma (PRP) combined with a new exercise care intervention (i.e., initiating strength and weight-bearing training within 24 hours after PRP injection).

Intervention code:

组别:

对照组

样本量:

30

Group:

Control group

Sample size:

干预措施:

富血小板血浆(PRP)联合常规护理。

干预措施代码:

Intervention:

Platelet-rich plasma (PRP) combined with a traditional care intervention

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖南省 

市(区县):

长沙 

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

湖南省人民医院(湖南师范大学附属第一医院) 

单位级别:

三甲 

Institution
hospital:

Hunan Provincial People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

视觉模拟评分法(VAS)

指标类型:

主要指标

Outcome:

Visual Analog Scale (VAS)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

健康调查简表(SF-36)

指标类型:

次要指标

Outcome:

Short Form-36 (SF-36)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

纽卡斯尔护理满意度量表(NSNS)

指标类型:

次要指标

Outcome:

Newcastle Satisfaction with Nursing Scale (NSNS)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

美国特种外科医院膝关节功能(HSS)

指标类型:

次要指标

Outcome:

Hospital for Special Surgery Knee Score (HSS)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Lysholm评分

指标类型:

次要指标

Outcome:

Lysholm score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床效果(总有效率)

指标类型:

次要指标

Outcome:

Clinical effect (Total effective rate)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Excel生成随机数字

Randomization Procedure (please state who generates the random number sequence and by what method):

Excel random number

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

数据将存放在国家生物信息中心 (https://ngdc.cncb.ac.cn/gsub/),公开时间为2027/12/31,(注册号PRJCA058499)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Data will be stored in China National center for Bioinformation (https://ngdc.cncb.ac.cn/gsub/), publicly available at 2027/12/31, (PRJCA058499)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究的数据采集与管理主要由以下两部分构成: 病例记录表 (Case Record Form, CRF): 研究团队设计了标准化的纸质病例记录表(CRF),用于系统、完整地收集每位受试者的信息。该表格内容涵盖: 基线资料:包括患者姓名(或唯一编码)、年龄、性别、身体质量指数(BMI)、患肢、既往史(高血压、糖尿病、冠心病、内分泌系统疾病等)、吸烟及饮酒史。 治疗信息:PRP制备与注射的详细过程记录(如采血量、离心参数、注射时间等)。 观察指标:在指定时间点(治疗前、治疗后1月、6月、12月)记录的视觉模拟评分法(VAS)、健康调查简表(SF-36)、纽卡斯尔护理满意度量表(NSNS)、美国特种外科医院膝关节功能(HSS)、Lysholm评分等所有结局指标的具体数值。 临床效果评估:根据预设标准对患者进行治愈、缓解或无效的判定。 电子采集和管理系统 (Electronic Data Capture, EDC): 在完成纸质CRF的填写后,所有原始数据由经过培训的研究人员通过双人独立录入的方式,输入至 Microsoft Excel 电子表格中进行存储和初步管理。数据录入完成后,进行交叉核对以确保准确性。最终,使用 SPSS 26.0 统计软件包对导出的数据进行统计学分析。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data collection and management in this study primarily consisted of the following two components: Case Record Form (CRF): The research team designed a standardized paper-based Case Record Form (CRF) to systematically and completely collect information for each subject. The form covered the following: Baseline Data: Including patient name (or unique identification code), age, gender, Body Mass Index (BMI), affected limb, medical history (e.g., hypertension, diabetes, coronary heart disease, endocrine system diseases), and history of smoking and alcohol consumption. Treatment Information: Detailed records of the PRP preparation and injection process (such as blood collection volume, centrifugation parameters, injection time, etc.). Observation Indicators: Specific values for all outcome measures recorded at designated time points (before treatment, and at 1, 6, and 12 months after treatment), including the Visual Analog Scale (VAS), Short Form-36 Health Survey (SF-36), Newcastle Satisfaction with Nursing Scales (NSNS), Hospital for Special Surgery (HSS) knee score, and Lysholm score. Clinical Efficacy Evaluation: Assessment of patients as cured, improved, or ineffective according to pre-defined criteria. Electronic Data Capture (EDC) System: After the paper CRFs were completed, all raw data were entered by trained research personnel using a double-data entry method into Microsoft Excel spreadsheets for storage and preliminary management. After data entry, cross-verification was performed to ensure accuracy. Finally, the exported data were subjected to statistical analysis using the SPSS 26.0 software package

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-03-04 17:31:52